![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Production & Manufacturing
Breckenridge Announces Entry into Injectable Market with the Immediate Launch of Methylergonovine Maleate Injection
Breckenridge Pharmaceutical, Inc. announced the immediate launch of Methylergonovine Maleate Injection, USP 0.2mg/mL. This product is an AP rated generic to Methergine®, a product...
Press Releases
METTLER TOLEDO opens new Competence Center to help Middle-East labs and manufacturers enhance their processes and profitability
METTLER TOLEDO has launched its new Dubai Free Zone Competence Center (www.mt.com/ME-CompetenceCenter) on 9 November 2016. This new facility will offer advanced analytical support...
Industry Reports
Multi Packaging Solutions completes two strategic acquisitions: AJS Labels and i3 Plastic Cards
Multi Packaging Solutions a global leader in value-added print and packaging solutions for the healthcare, branded consumer, and multi-media markets, has completed two strategic...
Drug Research
AdAlta licenses Alzheimer’s disease-specific shark antibodies to Crossbeta Biosciences for therapeutic and diagnostic development
AdAlta Limited a biotechnology company specialising in the discovery and development of protein-based therapeutics, and Crossbeta Biosciences, a biotechnology company with unique technology for...
Industry Reports
Lexicon Pharmaceuticals acquires exclusive rights to development candidate for Neuropathic pain from its alliance with Bristol-Myers Squibb
Lexicon Pharmaceuticals Inc announced that it has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that...
Press Releases
Cytokinetics announces new results from Cosmic-Hf to be presented at the American Heart Association Scientific Sessions 2016
Cytokinetics announced that a new analysis of left atrial structure and function from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in...
Clinical Trials
Genfit says FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
GENFIT a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
